Science & ResearchAug 21, 2026
Genetic screening identifies glial adenosine as a therapeutic target in alpha-synucleinopathy
Neuronal alpha-synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), lack disease-modifying therapies.
Neuronal alpha-synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), lack disease-modifying therapies. We developed a Drosophila model for identifying novel glial-based therapeutic targets for alpha-synucleinopathies. In this model, human…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.